retatrutide weight loss clinical trials retatrutide Retatrutide, Eli Lilly's next generation of injections, showed dramatic results in trials, with patients losing an average of up to 71.2 pounds, or 28.7% of their body weight. Eli What the clinical trials say

What are the ethical considerations in prescribing GLP-1 agonists to women of childbearing potential, given the risks to fetal development and the necessity of contraception

In a 36-week phase II trial conducted among obese individuals, orforglipron dosages varied from 12 to 45 mg

Weight loss injections like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) have raised important questions about reproductive health

nor did it have any beneficial effects [19]

Alcohol: The company's provider guides advise limiting or avoiding alcohol during treatment, especially during dose adjustments, as it may worsen nausea, low blood sugar, or dehydration

For context, tirzepatide (Mounjaro) is a dual GIP/GLP-1 receptor agonist, and semaglutide (Wegovy, Ozempic) is a GLP-1 receptor agonist